Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Furiex Pharmaceuticals ( FURX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 2.3%. By the end of trading, Furiex Pharmaceuticals fell $1.59 (-2.0%) to $77.12 on light volume. Throughout the day, 175,147 shares of Furiex Pharmaceuticals exchanged hands as compared to its average daily volume of 349,400 shares. The stock ranged in price between $76.02-$79.72 after having opened the day at $79.23 as compared to the previous trading day's close of $78.71. Other companies within the Drugs industry that declined today were: Ultragenyx Pharmaceutical ( RARE), down 9.4%, Fibrocell Science ( FCSC), down 8.2%, Merus Labs International ( MSLI), down 7.4% and uniQure ( QURE), down 6.9%.

Furiex Pharmaceuticals, Inc. operates as a drug development company that is involved in compound development and collaboration activities primarily in the United States. Furiex Pharmaceuticals has a market cap of $837.3 million and is part of the health care sector. Shares are up 87.4% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Furiex Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Furiex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally high debt management risk.

On the positive front, Apricus Biosciences ( APRI), up 18.9%, Alliqua ( ALQA), up 17.1%, Tetraphase Pharmaceuticals ( TTPH), up 14.4% and TrovaGene ( TROV), up 12.1% , were all gainers within the drugs industry with Celgene Corporation ( CELG) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.